March 9, 2026
Defence Therapeutics Inc.
ISIN: CA24463V1013
Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
Montreal, QC, Canada, March 9, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology and precision intracellular drug-delivery company, is...
Read more >>Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March
Montreal, QC, Canada, March 2nd, 2026 -- Defence Therapeutics Inc. (“Defence” or the “Company”), a publicly traded biotechnology company advancing next-generation therapeutics using its proprietary Accum® platform, today outlined its...
Read more >Defence Therapeutics Aligns Accum ADC Strategy through Multidisciplinary Scientific Advisory Board
Montreal, QC, Canada, February 10th, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), a publicly traded biotechnology and precision intracellular drug-delivery company, reported on its Scientific Advisory Board (“SAB”)...
Read more >Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform
Montreal, QC, Canada, February 4th, 2026 – Defence Therapeutics Inc. (“Defence” or the “Company”), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced that it will present at...
Read more >Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate its Proprietary Radiopharmaceutical Pipeline
Montreal, QC, Canada, January 28th, 2026 - Defence Therapeutics Inc. (“Defence” or the “Company”), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced the strengthening of its long-standing...
Read more >Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics
Montreal, QC, Canada, January 21st, 2026 - Defence Therapeutics Inc., (“Defence” or the “Company”), a publicly traded biotechnology company, today announced an evolution of its corporate positioning to reflect its...
Read more >Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs
Montreal, QC, Canada, December 4th, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more...
Read more >Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs
Montreal, QC, Canada, December 4th, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more...
Read more >Defence Therapeutics to Build ADC Drug Delivery Powerhouse Using its Proprietary Accum Technology
Montreal, QC, Canada, November 19th, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company pioneering next-generation antibody-drug conjugate (“ADC”), is pleased to announce a major step...
Read more >